Syneos Health and Elligo Announce Strategic Collaboration
Austin, TX and Raleigh, NC — Syneos Health™ (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, and Elligo Health Research, the only platform that brings clinical research direct to clinical health care, are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients. Both companies share a vision to evolve the clinical trial paradigm to speed the delivery of biopharmaceutical therapies to market.
Syneos Health is a top three Contract Research Organization (CRO) that combines comprehensive and integrated outsourcing solutions for both clinical development and commercialization. Elligo Health Research deploys an approach that improves clinical trial access by engaging the 97 percent of physicians currently not offering clinical research to their patients.
Applying its Goes Direct® approach, Elligo identifies patients for clinical trials using electronic health records and then provides their physicians with the infrastructure to conduct the research in their own practices. This platform enables research at practices that historically would not have had the infrastructure to conduct clinical research. Syneos Health will collaborate with Elligo to pilot new ways of quickly finding patients to enlist them in clinical trial research.
The collaboration will seek to build a centrally managed infrastructure and regulatory research system around physicians and patients who have not typically been accessible in traditional sites. This could include deploying expert staff and providing the training and regulatory guidance needed to run a trial, removing physician burden and focusing the experience around the patient.
The ability to bring clinical research to underrepresented populations through community medical practices, evolving from a location-bound approach, to a centrally managed systemic approach, redefines the clinical trial site footprint. This effort should improve quality, reduce timelines and save costs.
“Our biopharma acceleration model is designed to completely surround the patient, caregiver or any stakeholder with the most relevant solutions to make the clinical trial process easier and more accessible. Our collaboration with Elligo allows us to do just that,” said Alistair Macdonald, chief executive officer, Syneos Health. “By leveraging data, technology and trusted physician relationships, we believe we can radically reduce enrollment times and impact health outcomes on behalf of our customers.”
“We are thrilled to collaborate with Syneos Health to create a system of accelerated research that expands our vision of engaging the patient and physician in clinical research,” said John Potthoff, Ph.D., chief executive officer, Elligo. “Not only are we maximizing clinical trial process efficiencies, we’re transforming the clinical trial paradigm with deeper insights and more actionable real-world evidence.”
About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.
Elligo Health Research offers the only platform that brings clinical research to physician practices, accelerating the development of new pharmaceutical, biotechnology and medical device products and therapies. Our Goes Direct® approach uses state-of-the-art technology to compliantly leverage current electronic health record data and applies a proprietary, prescreening process to match protocol-eligible patients for participation in clinical studies. It is our mission to support health care providers by providing personnel, procedures, technology and infrastructure for clinical research, enabling patients to participate in research while remaining under the care of their own trusted physician. Learn more at elligodirect.com.